Antoni Farre

Antoni Farre

Auto-generated profile, based on publicly available information

Antoni Farre

Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EMEsther Molina-Montes
Esther Molina-Montes
LHLisa Van Hoogstraten
Lisa Van Hoogstraten
PGPaulina Gomez-Rubio
Paulina Gomez-Rubio
MLMatthias Löhr
Matthias Löhr
LSLinda Sharp
Linda Sharp
NMNuria Malats
Nuria Malats
Background: Despite smoking being a well-established risk factor for pancreatic cancer, there is a need to further characterize pancreatic cancer risk according to lifespan smoking patterns and other smoking features, such as tobacco type. Our aim was to deeply investigate them within a large European case–control study.Methods: Tobacco smoking habits and other relevant information were obtained from 2,009 cases and 1,532 controls recruited in the PanGenEU study using standardized tools. Multivariate logistic regression analysis was performed to evaluate pancreatic cancer risk by smoking characteristics and interactions with other pancreatic cancer risk factors. Fractional polynomials and restricted cubic splines were used to test for nonlinearity of the dose–response relationships and to analyze their shape.Results: Relative to never-smokers, current smokers [OR = 1.72; 95% confidence interval (95% CI), 1.39–2.12], those inhaling into the throat (OR = 1.48; 95% CI, 1.11–1.99) or chest (OR = 1.33; 95% CI, 1.12–1.58), and those using nonfiltered cigarettes (OR = 1.69; 95% CI, 1.10–2.61), were all at an increased pancreatic cancer risk. Pancreatic cancer risk was highest in current black tobacco smokers (OR = 2.09; 95% CI, 1.31–3.41), followed by blond tobacco smokers (OR = 1.43; 95% CI, 1.01–2.04). Childhood exposure to tobacco smoke relative to parental smoking was also associated with increased pancreatic cancer risk (OR = 1.24; 95% CI, 1.03–1.49). Dose–response relationships for smoking duration, intensity, cumulative dose, and smoking cessation were nonlinear and showed different shapes by tobacco type. Effect modification by family history of pancreatic cancer and diabetes was likely.Conclusions: This study reveals differences in pancreatic cancer risk by tobacco type and other habit characteristics, as well as nonlinear risk associations.Impact: This characterization of smoking-related pancreatic cancer risk profiles may help in defining pancreatic cancer high-risk populations.

1 September 2014 in Pancreatology
Verified
Journal Article
Closed access
OBOlaf J. Bakker
Olaf J. Bakker
SBSandra van Brunschot
Sandra van Brunschot
AFAntoni Farre
Antoni Farre
CJColin D. Johnson
Colin D. Johnson
FKFotis Kalfarentzos
Fotis Kalfarentzos
HGHein G. Gooszen
Hein G. Gooszen

7 November 2012 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
MGMireia Morell Ginestà
Mireia Morell Ginestà
JMJosefina Mora
Josefina Mora
RMRegina Mayor
Regina Mayor
AFAntoni Farré
Antoni Farré
MPMiquel Angel Peinado
Miquel Angel Peinado
JFJoan Fabregat
Joan Fabregat
Background: Methylation markers have shown promise in the early diagnosis of pancreatic carcinoma. The aim of this study was to assess the diagnostic utility of hypermethylation status of candidate genes in combination with KRAS mutation detection in the evaluation of pancreatic masses. Experimental design: Sixty-one fine needle aspirates of pancreatic masses (43 pancreatic adenocarcinomas and 18 chronic pancreatitis) were studied. Methylation status of HRH2, EN1, SPARC, CDH13 and APC were analysed using melting curve analysis after DNA bisulfite treatment. KRAS mutations were also analysed. Results: The methylation panel had a sensitivity of 73% (27 of 37, CI 95% 56 to 86%) and a specificity of 100% whenever two or more promoters were found hypermethylated. KRAS mutations showed a sensitivity of 77% (33 of 43, CI 95% 62 to 88%) and a specificity of 100%. Both molecular analyses added useful information to cytology by increasing the number of informative cases. When genetic and epigenetic analyses were combined sensitivity was 84% (36 of 43 CI 95% 69 to 93%) maintaining a 100% specificity. Conclusions: Analysis of hypermethylation status of a panel of genes and KRAS mutation detection offer a similar diagnostic yield in the evaluation of pancreatic masses. The combined molecular analysis increases the number of informative cases without diminishing specificity.

1 May 2013 in Gastroenterology
Verified
Journal Article
Closed access
OBOlaf J. Bakker
Olaf J. Bakker
SBSandra van Brunschot
Sandra van Brunschot
AFAntoni Farre
Antoni Farre
CJColin D. Johnson
Colin D. Johnson
FKFotis Kalfarentzos
Fotis Kalfarentzos
HGHein G. Gooszen
Hein G. Gooszen